|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian
L, Wei J, Yang X, Shen Q, Gong Z and Yan Y: SIRT5 downregulation is
associated with poor prognosis in glioblastoma. Cancer Biomark.
24:449–459. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coleman MP, Forman D, Bryant H, Butler J,
Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, et al:
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and
the UK, 1995–2007 (the International Cancer Benchmarking
Partnership): An analysis of population-based cancer registry data.
Lancet. 377:127–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kane AE and Sinclair DA: Sirtuins and
NAD+ in the development and treatment of metabolic and
cardiovascular diseases. Circ Res. 123:868–885. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh CK, Chhabra G, Ndiaye MA,
Garcia-Peterson LM, Mack NJ and Ahmad N: The role of sirtuins in
antioxidant and redox signaling. Antioxid Redox Signal. 28:643–661.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Callaghan C and Vassilopoulos A:
Sirtuins at the crossroads of stemness, aging, and cancer. Aging
Cell. 16:1208–1218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karbasforooshan H, Roohbakhsh A and Karimi
G: SIRT1 and microRNAs: The role in breast, lung and prostate
cancers. Exp Cell Res. 367:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Y, Lin J, Lin Y, Chen X, Zhu G and
Huang G: Overexpression of SIRT4 inhibits the proliferation of
gastric cancer cells through cell cycle arrest. Oncol Lett.
17:2171–2176. 2019.PubMed/NCBI
|
|
11
|
Park EY, Woo Y, Kim SJ, Kim DH, Lee EK, De
U, Kim KS, Lee J, Jung JH, Ha KT, et al: Anticancer effects of a
new SIRT inhibitor, MHY2256, against human breast cancer MCF-7
cells via regulation of MDM2-p53 binding. Int J Biol Sci.
12:1555–1567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang G, Cui F, Yu F, Lu H, Zhang M, Tang
H and Peng Z: Sirtuin-4 (SIRT4) is downregulated and associated
with some clinicopathological features in gastric adenocarcinoma.
Biomed Pharmacother. 72:135–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HS, Vassilopoulos A, Wang RH, Lahusen
T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2
maintains genome integrity and suppresses tumorigenesis through
regulating APC/C activity. Cancer Cell. 20:487–499. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Azuma Y, Yokobori T, Mogi A, Altan B,
Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M and
Kuwano H: SIRT6 expression is associated with poor prognosis and
chemosensitivity in patients with non-small cell lung cancer. J
Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shuang T, Wang M, Zhou Y and Shi C:
Over-expression of Sirt1 contributes to chemoresistance and
indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Med Oncol. 32:2602015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pinton G, Nilsson S and Moro L: Targeting
estrogen receptor beta (ERβ) for treatment of ovarian cancer:
Importance of KDM6B and SIRT1 for ERβ expression and functionality.
Oncogenesis. 7:152018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Y, Gao WN, Xue YN, Zhang LC, Zhang JJ,
Lu SY, Yan XY, Yu HM, Su J and Sun LK: SIRT3 aggravates
metformin-induced energy stress and apoptosis in ovarian cancer
cells. Exp Cell Res. 367:137–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bae JS, Noh SJ, Kim KM, Park SH, Hussein
UK, Park HS, Park BH, Ha SH, Lee H, Chung MJ, et al: SIRT6 is
involved in the progression of ovarian carcinomas via
β-catenin-mediated epithelial to mesenchymal transition. Front
Oncol. 8:5382018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M,
Zhang H, Chen SF and Yao LQ: The histone deacetylase SIRT6 inhibits
ovarian cancer cell proliferation via down-regulation of Notch 3
expression. Eur Rev Med Pharmacol Sci. 19:818–824. 2015.PubMed/NCBI
|
|
21
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Györffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin L, Qiu H, Zhang M, Zhang F, Yang H,
Yang L, Jia L, Qin K, Jia L, Dou X, et al: Soluble CD40 ligands
sensitize the epithelial ovarian cancer cells to cisplatin
treatment. Biomed Pharmacother. 79:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giannopoulou AF, Velentzas AD,
Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros
NI, Mpakou VE, Iconomidou V, Anastasiadou E, et al: Revisiting
histone deacetylases in human tumorigenesis: The paradigm of
urothelial bladder cancer. Int J Mol Sci. 20:2019. View Article : Google Scholar
|
|
26
|
Huang G and Zhu G: Sirtuin-4 (SIRT4), a
therapeutic target with oncogenic and tumor-suppressive activity in
cancer. Onco Targets Ther. 11:3395–3400. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geng CH, Zhang CL, Zhang JY, Gao P, He M
and Li YL: Overexpression of Sirt6 is a novel biomarker of
malignant human colon carcinoma. J Cell Biochem. 119:3957–3967.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Serrano L, Martínez-Redondo P,
Marazuela-Duque A, Vazquez BN, Dooley SJ, Voigt P, Beck DB,
Kane-Goldsmith N, Tong Q, Rabanal RM, et al: The tumor suppressor
SirT2 regulates cell cycle progression and genome stability by
modulating the mitotic deposition of H4K20 methylation. Genes Dev.
27:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee BB, Kim Y, Kim D, Cho EY, Han J, Kim
HK, Shim YM and Kim DH: Metformin and tenovin-6 synergistically
induces apoptosis through LKB1-independent SIRT1 down-regulation in
non-small cell lung cancer cells. J Cell Mol Med. 23:2872–2889.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shin DH, Choi YJ and Park JW: SIRT1 and
AMPK mediate hypoxia-induced resistance of non-small cell lung
cancers to cisplatin and doxorubicin. Cancer Res. 74:298–308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu L, Dong Q, He J, Wang X, Xing J, Wang
E, Qiu X and Li Q: SIRT4 inhibits malignancy progression of NSCLCs,
through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Oncogene. 36:2724–2736. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS,
Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis for breast
carcinoma. Human Pathol. 42:204–213. 2011. View Article : Google Scholar
|
|
33
|
Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R,
Yang S and Zhang N: SIRT1 promotes formation of breast cancer
through modulating Akt activity. J Cancer. 9:2012–2023. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jeong SM, Xiao C, Finley LW, Lahusen T,
Souza AL, Pierce K, Li YH, Wang X, Laurent G, German NJ, et al:
SIRT4 has tumor-suppressive activity and regulates the cellular
metabolic response to DNA damage by inhibiting mitochondrial
glutamine metabolism. Cancer Cell. 23:450–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH,
Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis of gastric
carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun H, Huang D, Liu G, Jian F, Zhu J and
Zhang L: SIRT4 acts as a tumor suppressor in gastric cancer by
inhibiting cell proliferation, migration, and invasion. Onco
Targets Ther. 11:3959–3968. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Byles V, Zhu L, Lovaas JD, Chmilewski LK,
Wang J, Faller DV and Dai Y: SIRT1 induces EMT by cooperating with
EMT transcription factors and enhances prostate cancer cell
migration and metastasis. Oncogene. 31:4619–4629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Csibi A, Fendt SM, Li C, Poulogiannis G,
Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T,
et al: The mTORC1 pathway stimulates glutamine metabolism and cell
proliferation by repressing SIRT4. Cell. 153:840–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pryds K, Nielsen RR, Jorsal A, Hansen MS,
Ringgaard S, Refsgaard J, Kim WY, Petersen AK, Bøtker HE and
Schmidt MR: Effect of long-term remote ischemic conditioning in
patients with chronic ischemic heart failure. Basic Res Cardiol.
112:672017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dong XC, Jing LM, Wang WX and Gao YX:
Down-regulation of SIRT3 promotes ovarian carcinoma metastasis.
Biochem Biophys Res Commun. 475:245–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen XF, Tian MX, Sun RQ, Zhang ML, Zhou
LS, Jin L, Chen LL, Zhou WJ, Duan KL, Chen YJ, et al: SIRT5
inhibits peroxisomal ACOX1 to prevent oxidative damage and is
downregulated in liver cancer. EMBO Rep. 19:2018. View Article : Google Scholar
|
|
43
|
Wang YQ, Wang HL, Xu J, Tan J, Fu LN, Wang
JL, Zou TH, Sun DF, Gao QY, Chen YX and Fang JY: Sirtuin5
contributes to colorectal carcinogenesis by enhancing
glutaminolysis in a deglutarylation-dependent manner. Nat Commun.
9:5452018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li N, Mao D, Cao Y, Li H, Ren F and Li K:
Downregulation of SIRT6 by miR-34c-5p is associated with poor
prognosis and promotes colon cancer proliferation through
inhibiting apoptosis via the JAK2/STAT3 signaling pathway. Int J
Oncol. 2018.
|
|
47
|
Wei W, Jing ZX, Ke Z and Yi P: Sirtuin 7
plays an oncogenic role in human osteosarcoma via downregulating
CDC4 expression. Am J Cancer Res. 7:1788–1803. 2017.PubMed/NCBI
|
|
48
|
Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B,
Ji M and Hou P: SIRT7 promotes thyroid tumorigenesis through
phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1
axis. Oncogene. 38:345–359. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
He WZ and Xia LP: RE: Detecting overall
survival benefit derived from survival postprogression rather than
progression-free survival. J Natl Cancer Inst. Oct 16–2015.(Epub
ahead of print). doi: 10.1093/jnci/djv311.
|
|
50
|
Sundar S, Wu J, Hillaby K, Yap J and
Lilford R: A systematic review evaluating the relationship between
progression free survival and post progression survival in advanced
ovarian cancer. Gynecol Oncol. 125:493–499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shimokawa M, Ohki M and Kaku T:
Correlation of progression-free and post-progression survival with
overall survival in phase III trials of first-line chemotherapy for
advanced epithelial ovarian cancer. Eur J Gynaecol Oncol.
36:370–375. 2015.PubMed/NCBI
|
|
52
|
Telloni SM: Tumor staging and grading: A
primer. Methods Mol Biol. 1606:1–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Šišovská I, Minář L, Felsinger M, Anton M,
Bednaříková M, Hausnerová J, Jandáková E and Weinberger V: Current
FIGO staging classification for cancer of ovary, fallopian tube and
peritoneum. Ceska Gynekol. 82:230–236. 2017.(In Czech). PubMed/NCBI
|
